Bellerophon
8
0
0
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
25.0%
2 terminated/withdrawn out of 8 trials
50.0%
-36.5% vs industry average
0%
0 trials in Phase 3/4
50%
1 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Role: lead
Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19
Role: lead
Expanded Access for Patients With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Role: lead
Effect iNO on Functional Respiratory Imaging in Subjects With WHO Group 3 Pulmonary Hypertension With COPD on Oxygen
Role: lead
3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF
Role: lead
A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis
Role: lead
Inhaled Nitric Oxide for Preventing Progression in COVID-19
Role: collaborator
Inhaled NO in IPF and COPD During 6 Minute Walk Test
Role: collaborator
All 8 trials loaded